Metabolon, a Morrisville, NC-based company which specialises in providing metabolomics solutions for life science research, diagnostic, therapeutic development, and precision medicine applications, received a $60M credit facility.
Trinity Capital made the financing.
The company intends to use the funds to further enhance its growth initiatives and expand its research and development efforts to further enhance its metabolomics platform. The financing will also support Its global expansion plans, including market penetration initiatives and strategic partnerships.
Led by CEO Rohan (Ro) Hastie, Metabolon is the global leader in metabolomics with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed scientific, technology, and bioinformatics techniques. Its Global Discovery Panel is enabled by a large proprietary metabolomics reference library. Its data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics supporting customer needs from discovery through clinical trials and product life-cycle management.
Commenting on the news, Rohan (Ro) Hastie said: “As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space.”